Meet the leaders and members of the Leukemia Research program at the OSUCCC – James who work to develop targeted therapies for leukemia.

Leaders

John Byrd, MD

Dr. Byrd’s research accomplishments relate best to studies done between the laboratory and clinic (translational work) with several different therapeutic agents active in chronic lymphocytic leukemia (CLL) and related leukemias and lymphomas. His work has shown that therapeutic agents such as.

Read More

Ramiro Garzon, MD

My laboratory is interested in discovering the role of non-coding RNAs in normal Blood formation and how these RNAs may cooperate with other protein coding genes during leukemogenesis

Read More

Members

Lynne Abruzzo, MD, PhD

Lynne Abruzzo, MD, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where she centers her research on low-grade B-cell leukemia and lymphoma, including chronic lymphocytic leukemia (CLL). She is a co-holder of 17 patents in the United States and other countries for breast.

Read More

Lapo Alinari, MD, PhD

Lapo Alinari, MD, PhD, is an Assistant Professor of Internal Medicine in the Division of Hematology and a member of the Leukemia Research Program at the OSUCCC – James. Dr. Alinari’s research focuses on the identification of novel targets and preclinical as well as clinical development of.

Read More

Jeffrey Auletta, MD

Dr. Jeffery Auletta Jeffery Auletta, MD, is a member of the Leukemia Research Program at the OSUCCC – James. Dr. Auletta is the Director of the Pediatric Blood and Marrow Transplant Program at Nationwide Children’s Hospital, which works closely with the OSUCCC – James Cell Therapy Lab and Adult.

Read More

Robert Baiocchi, MD, PhD

Robert Baiocchi, MD, PhD, is a member of the Leukemia Research Program at the OSUCCC – James. His work has led to 11 patents and pending patents, including one for methods to treat viral-associated lymphoproliferative disorders with TGF-ß antagonists, one for compositions and methods relating to.

Read More

Sharyn Baker, PharmD, PhD

Dr. Baker’s cancer-relevant research interests broadly cover translational and clinical pharmacology of anti-cancer agents. Recently, her laboratory has focused on the preclinical development of anti-cancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine.

Read More

Bhavana Bhatnagar, DO

My primary clinical interest is acute myeloid leukemia (AML) and my research interests pertain to : 1 -The development and application of novel therapies in early phase clinical trials that are both effective and well-tolerated for the treatment of poor-risk AML, particularly in the

Read More

James Blachly, MD

Dr. Blachly's interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics; namely, whether and how mutations and transcriptional attributes (including gene expression level, but also alternative splicing, alternative polyadenylation, non-protein coding

Read More

Brad Blaser, MD, PHD

I am interested in identifying factors in the hematopoietic niche that promote the development of myeloid neoplasia. I will use patient samples from the OSUCCC Leukemia Tissue Bank to identify candidate genes which will be screened for effects on blood stem cells in the zebrafish system using.

Read More

Clara Bloomfield, MD

After serving as director of the OSU Comprehensive Cancer Center from 1997 to July 2003, Dr. Bloomfield became Senior Advisor to the OSU cancer program and the charter member of the OSU Cancer Scholars Program, which is designed to help recruit and retain senior cancer investigators of

Read More

Jon Butchar, PhD

As a member of the Leukemia Research Program at the OSUCCC – James, Jonathan Butchar, PhD, seeks to improve the efficacy of antibody therapy through his research. His work brings together pathogenesis and tumor immunotherapy by studying interactions between Fc-gamma receptor and Toll-like.

Read More

Carlos Castro, PhD

Carlos Castro, PhD, brings an engineering perspective as a member of the Leukemia Research Program at the OSUCCC – James. He seeks to use engineering approaches with nanotechnology and biophysics experimental tools to characterize and model physical properties and behaviors of complex.

Read More

Beth Christian, MD

Beth Christian, MD, is a member of The Ohio State University Comprehensive Cancer Center, where she focuses her research on experimental therapeutics of B-cell non-Hodgkin and Hodgkin lymphoma. Her clinical research includes serving as the principal investigator and co-investigator on numerous.

Read More

Adrienne Dorrance, PhD

Adrienne Dorrance, PhD, is a member of the Leukemia Research Progam at the OSUCCC – James. Through a collaborative approach that crosses four colleges and 11 academic departments, her team examines all molecular aspects of tumor cells, integrating those features to improve leukemia risk.

Read More

Christina Drenberg Guttke, PhD

Christina Diane Drenberg Guttke, PhD, is a member of the Leukemia Research Program at OSUCCC – James, where her research focuses on identifying therapeutic strategies to improve the long-term outcome for pediatric acute myeloid leukemia patients. In particular, she integrates genomic and.

Read More

Yvonne Efebera, MD

The development of osteolytic bone disease in Multiple Myeloma (MM) is the result of increased osteoclastic bone resorption and impairment of osteoblastic bone formation. The Wnt signaling pathway is important for osteoblastic differentiation.

Read More

Aharon Freud, MD, PhD

As a member of the Leukemia Research Program at the OSUCCC – James, Aharon G. Freud, MD, PhD, seeks to understand how natural killer (NK) cells develop in healthy and diseased settings so that processes can be modulated to promote effective NK cell anticancer functions.

Read More

Patrick Green, PhD

Patrick Green, PhD, is a professor and associate dean for research and graduate studies in the College of Veterinary Medicine at Ohio State, where he also directs the Center for Retrovirus Research and is a member of the OSUCCC – James Leukemia Research Program. Dr. Green’s research focuses on.

Read More

Michael Grever, MD

Dr. Grever has over 30 years of experience in experimental chemotherapy and drug development for patients with chronic lymphocytic leukemia (CLL) and other hematologic malignancies. He performed the initial phase I studies on purine nucleoside analogs in patients with hematologic malignancies and.

Read More

Nicole Grieselhuber, MD, PhD

My primary research focus is translational research on myeloid malignancies. Current research projects include pre-clinical investigations of BET inhibitors in combination with other targeted therapies in pre-clinical models of acute myeloid leukemia and basic investigations into the role of BET.

Read More

H Grimes, PhD

H. Leighton Grimes, PhD, is a Professor in the Division of Immunobiology and Center for Systems Immunology at the Cincinnati Children’s Hospital Medical Center.

Read More

Nyla Heerema, PhD

Nyla Heerema, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where she focuses her research on chromosomal abnormalities in hematologic malignancies. In particular, Dr. Heerema’s work involves studying chromosome changes in pediatric acute lymphoblastic leukemia.

Read More

Erin Hertlein, PhD

Erin Hertlein, PhD, is a member of the Leukemia Research Program at the OSUCCC – James. Her research centers on NF-KB and other cancer-relevant cell signaling pathways.

Read More

Gang Huang, PhD

Gang Huang, PhD, is a member of the Leukemia Research Program at the OSUCCC – James and is based at Cincinnati Children’s Hospital Medical Center. His work focuses on genetic and epigenetic regulations of normal blood-cell development and leukemia.

Read More

Samantha Jaglowski, MD

Samantha Jaglowski, MD, MPH, is a member of the Leukemia Research Program at the OSUCCC – James. Her research focuses on cellular therapies for hematologic malignancies including engineered cell therapies for B cell malignancies as well as the treatment and prevention of complications of blood and.

Read More

Rosa Lapalombella, PhD

Rosa Lapalombella, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where she focuses her research on epigenetic alterations of cancer cells and the development of experimental therapeutics for hematologic disease. She is the co-holder of a patent for methods and.

Read More

Dean Lee, MD, PhD

Dr. Lee is a physician scientist with formal training and expertise in pediatric oncology, immunology, and clinical trials. My translational and early-phase clinical research developed after identifying a crucial role for IL-21 and STAT3 signaling in NK cell function and proliferation.

Read More

L. James Lee, PhD

L. James Lee, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where his research focuses on polymer engineering of nanomaterials and nanotechnology as they apply to BioMEMS (Bio-Micro-Electro-Mechanical Systems).

Read More

Robert J Lee, PhD

Robert J. Lee, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where his research centers on nanoparticle-based drug delivery systems. Dr. Lee is focused on improving nanoparticle composition based on rational design and directed at clinical applications.

Read More

Gerard Lozanski, MD

Gerard Lozanski, MD, is a member of the Leukemia Research Program at the OSUCCC – James. He also serves as director of hematopathology and as director of the Clinical Flow Cytometry Laboratory at The Ohio State University Wexner Medical Center.

Read More

David Lucas, PhD

David Lucas, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where his work focuses on the pharmacology of novel anti-leukemic agents and on the role of transcriptional and translational regulation in tumor cell survival and drug resistance. Among his recent research.

Read More

Alice Mims, MD, MSCR

Dr. Mims' clinical/translational research focus is on novel therapeutics in Acute Myeloid Leukemia (AML), in particular, for patients with high-risk disease such as the elderly (= 60 years), TP53 mutated, and relapsed/refractory disease. Her laboratory background began in medical school and.

Read More

Bethany Mundy-Bosse, PhD

My research is focused on defining the mechanisms driving innate immune cell defects in cancer patients, primarily hematologic malignancies.

Read More

Natarajan Muthusamy, DVM, PhD

Natarajan Muthusamy, DVM, PhD, is a member of the Leukemia Research Program at the OSUCCC – James. His research focuses on several areas, including biological therapies for hematologic malignancies, the development and characterization of clinically relevant animal models of lymphoid.

Read More

Stefan Niewiesk, DVM, PhD

Stefan Niewiesk, DVM, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where his research explores the use of measles vaccine virus as oncolytic therapy for T-cell leukemia. In particular, he uses a mouse model of adult T-cell leukemia to understand the interaction.

Read More

Christopher Oakes, PhD

Dr. Oakes’ current research focuses on investigating the role of epigenetics in hematological malignancies, with a primary focus on understanding the evolution and impact of epigenetic programming on the cancer cell phenotype. As the mechanisms that promote changes to the tumor epigenome are.

Read More

Qishen Pang, PhD

Dr. Pang's lab studies how Fanconi anemia (FA) proteins function to prevent stress-induced apoptosis and clonal evolution of hematopoietic stem cells and progenitors. Dr. Pang aslo works on a project involving the mechanism by which nucleophosmin (NPM) promotes cell proliferation and suppresses.

Read More

John Perentesis, MD, FAAP

Dr. Perentesis' clinical research focuses on the development of molecularly targeted therapies for pediatric and adolescent cancer. His laboratory program focuses on complementary studies of leukemia biology and pharmacogenetics of childhood cancer therapy.

Read More

A Mitchell Phelps, PhD

Dr. Phelps' expertise is in analytical methodologies and data modeling to study the disposition of novel anti-cancer agents. His lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU.

Read More

Parvathi Ranganathan, PhD

Dr. Ranganathan, PhD is a member of the Leukemia Research Program at the OSUCCC-James. Dr. Ranganathan's primary research interest is to study the immunobiology of acute Graft-Versus-Host Disease (aGVHD) with the goal of developing selective immune suppression strategies that abrogate aGVHD.

Read More

Kerry Rogers, MD

I am an Assistant Professor in the Division of Hematology and practice as a physician caring for patients with chronic lymphocytic leukemia and hairy cell leukemia. My research focus is clinical and translational research in experimental therapeutics.

Read More

Deepa Sampath, PhD

Deepa Sampath, MD, is a member of the Leukemia Research Program at OSUCCC – James, where her research focuses on the epigenetics of lymphoid malignancies. One of her recent studies indicates a novel pharmacologic strategy that compromises the ability of acute myelogenous leukemia cells to.

Read More

Lalit Sehgal, MPhil, PhD

Lalit Sehgal, PhD, is a translational scientist and an assistant professor in the Division of Hematology at the OSUCCC – James. He was trained as a human geneticist and specializes in developing strategies for personalized therapy for lymphoid malignancies.

Read More

Dhvanit Shah, PhD

Dr. Shah's laboratory investigates the origin, development, and differentiation of hematopoietic stem cells (HSCs) to treat patients with leukemia, lymphoma, genetic blood disorders, and bone-marrow failure syndromes.

Read More

Daniel Starczynowski, PhD

Dr. Starczynowski's laboratory focuses on the molecular, cellular, and genetic basis of hematologic malignancies, with a specific focus on Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). They have uncovered aberrant activation of the innate immune pathway in MDS, and now find.

Read More

Lara Sucheston-Campbell, PhD

Lara Sucheston-Campbell, PhD, is a member of the Leukemia Research Program. As a genetic epidemiologist my research is focused on identifying, quantifying and characterizing relationships between exposures and genomic variation that modify susceptibility to complex cancer phenotypes.

Read More

Susheela Tridandapani, PhD

Susheela Tridandapani, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where her research focuses on molecular mechanisms of innate immune responses to bacterial pathogens and immunoglobulin G complexes. In particular, she is interested in the context of monoclonal.

Read More

Sumithira Vasu, MD

Dr. Vasu's clinical interests include acute myeloid leukemia, Allogeneic hematopoietic stem cell transplantation. Her research interests include pPharmacologic and Immunologic therapies in Allogeneic transplantation to pre-emptively manage relapse and GvHD.

Read More

Alison Walker, MD

Dr. Walker's research interests are in AML and MDS(Acute Myeloid Leukemia and Myelodysplastic Syndromes)

Read More

Basem William, MD

Basem William, MD, MRCP(UK), FACP, is a clinical investigator with focus on translational approaches to the treatment of lymphomas. His background in lymphoma and clinical investigation comes from fellowship training at the University of Nebraska; an international center of excellence for.

Read More

Jennifer Woyach, MD

Dr. Woyach’s research interests include chronic lymphocytic leukemia and other hematologic malignancies. Her laboratory research focuses on the role of Bruton’s Tyrosine Kinase (BTK) in the development and expansion of CLL as well as therapeutic BTK inhibition in CLL using murine and cellular.

Read More

Pearlly Yan, PhD

Dr. Yan's research uses sequencing approach to interrogate cancer and disease-related methylomes, developing novel sequencing library protocols and custom computation pipeline to capture the methylome at high resolution.

Read More

Yi Zheng, PhD

Yi Zheng, PhD, is a member of the Leukemia Research Program at OSUCCC – James and is based in the Pediatrics Department at the University of Cincinnati’s College of Medicine. His research focuses on physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis.

Read More

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

OR

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Find a Scientific Publication

Search for Clinical Trials